S-2

Table of contents:
Part A: General conditions for the preparation of compounds 7-15……………….S2 Part B: Antimicrobial and cytotoxic activities of compounds 1-16.....................S3-S4 Part C: 1 H and 13 C-NMR spectra for compounds 3-16…………………….....S5-S18
PART A : PREPARATION OF COMPOUNDS 7-15 2 >20 >20 >20 4.42 >20 >20 >20
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15 >20 >20 >20 2.03 17.14 >20 >20
16 >20 >20 >20 >20 >20 >20 >20 A549 = adenocarcinomic alveolar basal epithelial cells (CCL-185); HepG2= liver hepatocellular (CCL-8065); HT29= colorectal adenocarcinoma (HTB-38); MCF-7= breast carcinoma (HTB-22); RCC4-VA and RCC4-VHL = renal carcinoma; Fa2N4= immortalized human hepatocytes
